Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Ovarian Carcinoma
Interventions
- BIOLOGICAL: Bevacizumab
- DRUG: Carboplatin
- OTHER: Laboratory Biomarker Analysis
- DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
- DRUG: Veliparib
Sponsor
National Cancer Institute (NCI)
Collaborators